Back to Search
Start Over
0.75% ropivacaine may be a suitable drug in pregnant women undergoing urgent cesarean delivery during labor analgesia period.
- Source :
- BMC Anesthesiology; 6/25/2024, Vol. 24 Issue 1, p1-9, 9p
- Publication Year :
- 2024
-
Abstract
- Background: 3% chloroprocaine (CP) has been reported as the common local anesthetic used in pregnant women undergoing urgent cesarean delivery during labor analgesia period. However, 0.75% ropivacaine is considered a promising and effective alternative. Therefore, we conducted a randomized controlled trial to compare the effectiveness and safety of 0.75% ropivacaine with 3% chloroprocaine for extended epidural anesthesia in pregnant women. Methods: We conducted a double-blind, randomized, controlled, single-center study from November 1, 2022, to April 30, 2023. We selected forty-five pregnant women undergoing urgent cesarean delivery during labor analgesia period and randomized them to receive either 0.75% ropivacaine or 3% chloroprocaine in a 1:1 ratio. The primary outcome was the time to loss of cold sensation at the T4 level. Results: There was a significant difference between the two groups in the time to achieve loss of cold sensation (303, 95%CI 255 to 402 S vs. 372, 95%CI 297 to 630 S, p = 0.024). There was no significant difference the degree of motor block (p = 0.185) at the Th4 level. Fewer pregnant women required additional local anesthetics in the ropivacaine group compared to the chloroprocaine group (4.5% VS. 34.8%, p = 0.011). The ropivacaine group had lower intraoperative VAS scores (p = 0.023) and higher patient satisfaction scores (p = 0.040) than the chloroprocaine group. The incidence of intraoperative complications was similar between the two groups, and no serious complications were observed. Conclusions: Our study found that 0.75% ropivacaine was associated with less intraoperative pain treatment, higher patient satisfaction and reduced the onset time compared to 3% chloroprocaine in pregnant women undergoing urgent cesarean delivery during labor analgesia period. Therefore, 0.75% ropivacaine may be a suitable drug in pregnant women undergoing urgent cesarean delivery during labor analgesia period. Clinical trial number and registry URL: The registration number: ChiCTR2200065201; http://www.chictr.org.cn, Principal investigator: MEN, Date of registration: 31/10/2022. [ABSTRACT FROM AUTHOR]
- Subjects :
- CESAREAN section
PATIENT safety
BODY temperature regulation
RESEARCH funding
ROPIVACAINE
STATISTICAL sampling
BLIND experiment
LABOR pain (Obstetrics)
PREGNANT women
RANDOMIZED controlled trials
DESCRIPTIVE statistics
SURGICAL therapeutics
OBSTETRICAL analgesia
PROCAINE
INTRAOPERATIVE monitoring
SURGICAL complications
BODY temperature
DRUG efficacy
PAIN management
COMPARATIVE studies
CONFIDENCE intervals
PATIENT satisfaction
WOMEN'S health
EPIDURAL anesthesia
NERVE block
Subjects
Details
- Language :
- English
- ISSN :
- 14712253
- Volume :
- 24
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Anesthesiology
- Publication Type :
- Academic Journal
- Accession number :
- 178085510
- Full Text :
- https://doi.org/10.1186/s12871-024-02597-4